Table 1. Clinical and hematologic... | American Society of Hematology

Table 1.

Clinical and hematologic characteristics of patients with chronic ITP

Case no.	Age	Sex	Prior therapy	Duration of disease (mo)	Platelet count prior to rituximab (× 10⁹/IL)^*	Platelet counts after rituximab (× 10⁹/L)									Response duration (weeks)	Additional therapy during the study period	Additional therapy during the observation phase after rituximab treatment	Subsequent therapy
Case no.	Age	Sex	Prior therapy	Duration of disease (mo)	Platelet count prior to rituximab (× 10⁹/IL)^*	Week 1	Week 2	Week 3	Week 4	Week 6	Week 8	Week 10	Week 12	Week 16	Response duration (weeks)	Additional therapy during the study period		Subsequent therapy
1	20	F	P, Ig, DXM, aRh, S	12	2	2	6	4	3	44	121	408	385	392	56+	P^†
2	50	F	P, Ig, DXM, aRh, S, V	84	1	2	8	12	6	20	77	120	131	123	28+	P^†
3	40	F	P, Ig	36	10	38	21	5	9	7	25	6			—	P^†	P	P^‡
4	32	F	P, Ig	10	11	35	44	40	46	67	468	751	526	404	16+
5	26	M	P, Ig	12	14	27	39	45	42	49	273	668	474	386	14+
6	58	F	P, Ig	14	12	74	62	51	27	28	48	63	87	9	7	P^†	P	Cy
7	66	F	P, Ig, S	53	19	24	33	43	41	47	59	80	68	92	8+	P^†

Case no.	Age	Sex	Prior therapy	Duration of disease (mo)	Platelet count prior to rituximab (× 10⁹/IL)^*	Platelet counts after rituximab (× 10⁹/L)									Response duration (weeks)	Additional therapy during the study period	Additional therapy during the observation phase after rituximab treatment	Subsequent therapy
Case no.	Age	Sex	Prior therapy	Duration of disease (mo)	Platelet count prior to rituximab (× 10⁹/IL)^*	Week 1	Week 2	Week 3	Week 4	Week 6	Week 8	Week 10	Week 12	Week 16	Response duration (weeks)	Additional therapy during the study period		Subsequent therapy
1	20	F	P, Ig, DXM, aRh, S	12	2	2	6	4	3	44	121	408	385	392	56+	P^†
2	50	F	P, Ig, DXM, aRh, S, V	84	1	2	8	12	6	20	77	120	131	123	28+	P^†
3	40	F	P, Ig	36	10	38	21	5	9	7	25	6			—	P^†	P	P^‡
4	32	F	P, Ig	10	11	35	44	40	46	67	468	751	526	404	16+
5	26	M	P, Ig	12	14	27	39	45	42	49	273	668	474	386	14+
6	58	F	P, Ig	14	12	74	62	51	27	28	48	63	87	9	7	P^†	P	Cy
7	66	F	P, Ig, S	53	19	24	33	43	41	47	59	80	68	92	8+	P^†

P indicates prednisone; Ig, intravenous immunoglobulin; DXM, high-dose dexamethasone; S, splenectomy; VC, vitamin C; V, vincristine; aRh, anti-Rh immunoglobulin; Cy, pulse cyclophosphamide; Rtx, rituximab.

Nadir platelet count before rituximab infusion.

†

Daily prednisone doses ranged between 10 mg and 50 mg.

‡

This patient refused splenectomy and cytotoxic treatments.

View Large

This Feature Is Available To Subscribers Only